| Year |
Citation |
Score |
| Low-probability matches (unlikely to be authored by this person) |
| 1998 |
Magnus P, Lacour J, Evans PA, Rigollier P, Tobler H. Applications of the β-Azidonation Reaction to Organic Synthesis. α,β-Enones, Conjugate Addition, and γ-Lactam Annulation Journal of the American Chemical Society. 120: 12486-12499. DOI: 10.1021/Ja9829564 |
0.247 |
|
| 2010 |
Qin LY, Cole AG, Metzger A, Brescia MR, Saionz KW, Zhang JJ, Rigollier P, Wareing JR, Gstach H, Zimmermann J, Dolle RE, Baldwin JJ, Henderson I. A facile synthesis of novel 2-amino-6-arylmethyl-7-carboxamido-7,8- dihydropyrimido[5,4-f][1,4]thiazepin-5-ones Tetrahedron Letters. 51: 4486-4489. DOI: 10.1016/J.Tetlet.2010.06.070 |
0.227 |
|
| 2000 |
Rueeger H, Rigollier P, Yamaguchi Y, Schmidlin T, Schilling W, Criscione L, Whitebread S, Chiesi M, Walker MW, Dhanoa D, Islam I, Zhang J, Gluchowski C. Design, synthesis and SAR of a series of 2-substituted 4-amino-quinazoline neuropeptide Y Y5 receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 10: 1175-9. PMID 10866375 DOI: 10.1016/S0960-894X(00)00177-3 |
0.225 |
|
| 1993 |
Magnus P, Rigollier P, Lacour J, Tobler H. New trialkylsilyl enol ether chemistry: Intramolecular [2 + 2] cyclizations of β-amido triisopropylsilyl enol ethers Journal of the American Chemical Society. 115: 12629-12630. |
0.187 |
|
| 2004 |
Rueeger H, Gerspacher M, Buehlmayer P, Rigollier P, Yamaguchi Y, Schmidlin T, Whitebread S, Nuesslein-Hildesheim B, Nick H, Cricione L. Discovery and SAR of potent, orally available and brain-penetrable 5,6-dihydro-4H-3-thia-1-aza-benzo[e]azulen- and 4,5-dihydro-6-oxa-3-thia-1-aza-benzo[e]azulen derivatives as neuropeptide Y Y5 receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 14: 2451-7. PMID 15109631 DOI: 10.1002/chin.200437166 |
0.143 |
|
| 2010 |
MAGNUS P, RIGOLLIER P. ChemInform Abstract: New Mild Methodology for the Synthesis of α-Phenylthio and . alpha.-Phenylseleno Ketones. Cheminform. 24: no-no. DOI: 10.1002/chin.199310067 |
0.137 |
|
| 1992 |
Magnus P, Rigollier P. New mild methodology for the synthesis of α-phenylthio and α-phenylseleno ketones Tetrahedron Letters. 33: 6111-6114. DOI: 10.1016/S0040-4039(00)60019-9 |
0.134 |
|
| 2014 |
Bassilana F, Carlson A, DaSilva JA, Grosshans B, Vidal S, Beck V, Wilmeringwetter B, Llamas LA, Showalter TB, Rigollier P, Bourret A, Ramamurthy A, Wu X, Harbinski F, Plonsky S, et al. Target identification for a Hedgehog pathway inhibitor reveals the receptor GPR39. Nature Chemical Biology. 10: 343-9. PMID 24633354 DOI: 10.1038/Nchembio.1481 |
0.124 |
|
| 2007 |
Göschke R, Stutz S, Rasetti V, Cohen NC, Rahuel J, Rigollier P, Baum HP, Forgiarini P, Schnell CR, Wagner T, Gruetter MG, Fuhrer W, Schilling W, Cumin F, Wood JM, et al. Novel 2,7-dialkyl-substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamide transition state peptidomimetics are potent and orally active inhibitors of human renin. Journal of Medicinal Chemistry. 50: 4818-31. PMID 17824679 DOI: 10.1021/jm070314y |
0.111 |
|
| 2005 |
Jacoby E, Schuffenhauer A, Popov M, Azzaoui K, Havill B, Schopfer U, Engeloch C, Stanek J, Acklin P, Rigollier P, Stoll F, Koch G, Meier P, Orain D, Giger R, et al. Key aspects of the Novartis compound collection enhancement project for the compilation of a comprehensive chemogenomics drug discovery screening collection. Current Topics in Medicinal Chemistry. 5: 397-411. PMID 15892682 DOI: 10.2174/1568026053828376 |
0.091 |
|
| 2019 |
Velcicky J, Mathison CJN, Nikulin V, Pflieger D, Epple R, Azimioara M, Cow C, Michellys PY, Rigollier P, Beisner DR, Bodendorf U, Guerini D, Liu B, Wen B, Zaharevitz S, et al. Discovery of Orally Active Hydroxyethylamine Based SPPL2a Inhibitors. Acs Medicinal Chemistry Letters. 10: 887-892. PMID 31223443 DOI: 10.1021/acsmedchemlett.9b00044 |
0.089 |
|
| 2010 |
Magnus P, Lacour J, Evans PA, Rigollier P, Tobler H. ChemInform Abstract: Applications of the β-Azidonation Reaction to Organic Synthesis. α,β-Enones, Conjugate Addition, and γ-Lactam Annulation. Cheminform. 30: no-no. DOI: 10.1002/chin.199916052 |
0.087 |
|
| 2022 |
Lorthiois E, Gerspacher M, Beyer KS, Vaupel A, Leblanc C, Stringer R, Weiss A, Wilcken R, Guthy DA, Lingel A, Bomio-Confaglia C, Machauer R, Rigollier P, Ottl J, Arz D, et al. JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRAS for the Treatment of Solid Tumors. Journal of Medicinal Chemistry. PMID 36399068 DOI: 10.1021/acs.jmedchem.2c01438 |
0.072 |
|
| 2022 |
Weiss A, Lorthiois E, Barys L, Beyer KS, Bomio-Confaglia C, Burks H, Chen X, Cui X, de Kanter R, Dharmarajan L, Fedele C, Gerspacher M, Guthy DA, Head V, Jaeger A, ... ... Rigollier P, et al. Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent and Selective, Covalent Oral Inhibitor of KRASG12C. Cancer Discovery. PMID 35404998 DOI: 10.1158/2159-8290.CD-22-0158 |
0.069 |
|
| 2007 |
Maibaum J, Stutz S, Göschke R, Rigollier P, Yamaguchi Y, Cumin F, Rahuel J, Baum HP, Cohen NC, Schnell CR, Fuhrer W, Gruetter MG, Schilling W, Wood JM. Structural modification of the P2' position of 2,7-dialkyl-substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamides: the discovery of aliskiren, a potent nonpeptide human renin inhibitor active after once daily dosing in marmosets. Journal of Medicinal Chemistry. 50: 4832-44. PMID 17824680 DOI: 10.1021/jm070316i |
0.064 |
|
| 2018 |
Velcicky J, Bodendorf U, Rigollier P, Epple R, Beisner DR, Guerini D, Smith P, Liu B, Feifel R, Wipfli P, Aichholz R, Couttet P, Dix I, Widmer T, Wen B, et al. Discovery of the First Potent, Selective, and Orally Bioavailable Signal Peptide Peptidase-Like 2a (SPPL2a) Inhibitor Displaying Pronounced Immunomodulatory Effects In Vivo. Journal of Medicinal Chemistry. PMID 29359565 DOI: 10.1021/Acs.Jmedchem.7B01371 |
0.063 |
|
| 1998 |
Criscione L, Rigollier P, Batzl-Hartmann C, Rüeger H, Stricker-Krongrad A, Wyss P, Brunner L, Whitebread S, Yamaguchi Y, Gerald C, Heurich RO, Walker MW, Chiesi M, Schilling W, Hofbauer KG, et al. Food intake in free-feeding and energy-deprived lean rats is mediated by the neuropeptide Y5 receptor. The Journal of Clinical Investigation. 102: 2136-45. PMID 9854049 DOI: 10.1172/JCI4188 |
0.061 |
|
| 2003 |
Wood JM, Maibaum J, Rahuel J, Grütter MG, Cohen NC, Rasetti V, Rüger H, Göschke R, Stutz S, Fuhrer W, Schilling W, Rigollier P, Yamaguchi Y, Cumin F, Baum HP, et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochemical and Biophysical Research Communications. 308: 698-705. PMID 12927775 DOI: 10.1016/S0006-291X(03)01451-7 |
0.059 |
|
| 1990 |
Rigollier P, Young JR, Fowley LA, Stille JR. Regioselective cyclopentane ring formation mediated by titanocene chloride Journal of the American Chemical Society. 112: 9441-9442. DOI: 10.1021/Ja00181A082 |
0.057 |
|
| 2010 |
Boettcher A, Ruedisser S, Erbel P, Vinzenz D, Schiering N, Hassiepen U, Rigollier P, Mayr LM, Woelcke J. Fragment-based screening by biochemical assays: Systematic feasibility studies with trypsin and MMP12. Journal of Biomolecular Screening. 15: 1029-41. PMID 20855559 DOI: 10.1177/1087057110380455 |
0.01 |
|
| Hide low-probability matches. |